Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Dear Editor, Most recently,a new SARS-CoV-2 variant of concern(VOC),Omicron(B.1.1.529),was first reported to the World Health Organization(WHO)from South Africa and then quickly spread to many countries,1,2 posing a serious threat to current vaccine prevention and antibody therapeutic strategies.Several studies have reported that the Omicron variant successfully escapes from neutralizing antibodies elicited by COVID-19 vaccines or from COVID-19 convalescent patients.3,4 Therefore,the development of potent anti-Omicron agents is urgently needed.